VEGFA and neoplasm: Anti-angiogenic therapy (e.g., VEGF or tyrosine kinase inhibitors) may improve the efficacy of IO therapy given that tumor-associated angiogenesis is linked with immunosuppression in the tumor microenvironment [30].